A Review of Ferric Pyrophosphate Citrate (Triferic) Use in Hemodialysis Patients - PubMed (original) (raw)
Review
. 2016 Oct;38(10):2318-2323.
doi: 10.1016/j.clinthera.2016.08.012. Epub 2016 Sep 28.
Affiliations
- PMID: 27692637
- DOI: 10.1016/j.clinthera.2016.08.012
Review
A Review of Ferric Pyrophosphate Citrate (Triferic) Use in Hemodialysis Patients
Tyler Albright et al. Clin Ther. 2016 Oct.
Abstract
Purpose: The objective of this short review is to evaluate the efficacy of ferric pyrophosphate citrate and to determine its place in therapy based on the current published literature.
Methods: A literature search was conducted and pared down to yield 4 placebo controlled Phase II and III clinically relevant trials.
Findings: Ferric pyrophosphate citrate is a new intradialytic iron supplementation product that has been found to reduce the dose of erythropoiesis-stimulating agents and intravenous iron supplementation and to increase serum ferritin concentrations.
Implications: This agent may be administered to patients with stage 5 chronic kidney disease receiving hemodialysis as a new iron supplementation option to maintain hemoglobin, transferrin saturation, and ferritin concentrations.
Keywords: anemia; chronic kidney disease; ferric pyrophosphate citrate; hemodialysis; hemoglobin; soluble ferric pyrophosphate.
Copyright © 2016 Elsevier HS Journals, Inc. All rights reserved.
Similar articles
- Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients.
Fishbane SN, Singh AK, Cournoyer SH, Jindal KK, Fanti P, Guss CD, Lin VH, Pratt RD, Gupta A. Fishbane SN, et al. Nephrol Dial Transplant. 2015 Dec;30(12):2019-26. doi: 10.1093/ndt/gfv277. Epub 2015 Jul 13. Nephrol Dial Transplant. 2015. PMID: 26175145 Free PMC article. Clinical Trial. - Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers.
Pratt RD, Swinkels DW, Ikizler TA, Gupta A. Pratt RD, et al. J Clin Pharmacol. 2017 Mar;57(3):312-320. doi: 10.1002/jcph.819. Epub 2016 Oct 3. J Clin Pharmacol. 2017. PMID: 27557937 Free PMC article. Clinical Trial. - Pharmacokinetics of ferric pyrophosphate citrate administered via dialysate and intravenously to pediatric patients on chronic hemodialysis.
Pratt RD, Grimberg S, Zaritsky JJ, Warady BA. Pratt RD, et al. Pediatr Nephrol. 2018 Nov;33(11):2151-2159. doi: 10.1007/s00467-018-4014-3. Epub 2018 Jul 12. Pediatr Nephrol. 2018. PMID: 30003313 Free PMC article. Clinical Trial. - Ferric Pyrophosphate Citrate: A Novel Iron Replacement Agent in Patients Undergoing Hemodialysis.
Shah HH, Hazzan AD, Fishbane S. Shah HH, et al. Semin Nephrol. 2016 Mar;36(2):124-9. doi: 10.1016/j.semnephrol.2016.02.007. Semin Nephrol. 2016. PMID: 27236134 Review. - Ferric pyrophosphate citrate as an iron replacement agent for patients receiving hemodialysis.
Fishbane S, Shah HH. Fishbane S, et al. Hemodial Int. 2017 Jun;21 Suppl 1:S104-S109. doi: 10.1111/hdi.12554. Epub 2017 Apr 3. Hemodial Int. 2017. PMID: 28371161 Review.
Cited by
- Treatment of Iron Deficiency Anemia in CKD and End-Stage Kidney Disease.
Gutiérrez OM. Gutiérrez OM. Kidney Int Rep. 2021 Jun 5;6(9):2261-2269. doi: 10.1016/j.ekir.2021.05.020. eCollection 2021 Sep. Kidney Int Rep. 2021. PMID: 34514189 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical